Regulatory framework

Peptides in pharmacies, without a prescription, legal? What French law says

Why BPC-157 and retatrutide are not found in pharmacies, why “without a prescription” does not apply, and what separates a medicine from a reference material.

8 min read · Purpeptide Research Desk ·

Translated from the French original, which remains the reference version: lire en français →

A diagram contrasting the medicine route (marketing authorisation, pharmacy, prescription) with the reference material route reserved for in-vitro research

“BPC-157 pharmacy”, “retatrutide without prescription”, “are peptides legal”: these are among the most searched questions about peptides. They often rest on a misunderstanding — the assumption that every peptide belongs in the category of medicines.

This article describes the French framework as it applies to peptides. It is general information: it does not replace the advice of a lawyer, and it contains no information on use.

Medicine or reference material: the definition that decides everything

Article L.5111-1 of the French Public Health Code defines a medicine by two criteria, each of which is sufficient on its own.

  • By presentation: any substance presented as having curative or preventive properties with regard to human or animal disease.
  • By function: any substance that may be used in, or administered to, humans or animals with a view to establishing a diagnosis or to restoring, correcting or modifying physiological functions by a pharmacological, immunological or metabolic action.

The first criterion is the one that weighs most heavily on a seller. A peptide sold with a promise of cure, of “recovery” or of weight loss becomes a medicine by presentation, whatever its composition. A peptide sold as an analytical standard for in-vitro research, with no health claim at all, is not one by its presentation.

Why these peptides are not found in pharmacies

A pharmacy does not sell “molecules”: it dispenses medicines. And a medicine may be marketed only after obtaining a marketing authorisation, granted by the ANSM or at European level (article L.5121-8 of the Public Health Code). The sale of medicines to the public is moreover a monopoly of pharmacists (article L.4211-1).

BPC-157, TB-500, Semax, Epitalon and GHK-Cu as research materials hold no marketing authorisation in France. They therefore cannot appear in the pharmaceutical channel. This is not a stock shortage or a local restriction: that channel is simply not open to them.

“Without a prescription”: a phrase that does not apply

The categories “on prescription” and “without a prescription” are classifications of authorised medicines. A medicine subject to compulsory medical prescription is dispensed only against a prescription; a medicine of optional prescription may be recommended by the pharmacist.

A reference material belongs to neither of those two categories. Describing it as “sold without a prescription” implies it would be a freely available medicine — which is false. There is simply no possible prescription for a product that is not a medicine.

The peptides that are, for their part, medicines

The confusion also comes from the fact that many peptides are genuine medicines, authorised and prescribed. They then follow all the rules of the pharmaceutical channel.

PeptideStatus in FranceChannel
Semaglutide (Ozempic, Wegovy)Authorised medicinePharmacy, on prescription
Tirzepatide (Mounjaro)Authorised medicinePharmacy, on prescription
Oxytocin (Syntocinon)Authorised medicineHospital use
Bremelanotide (Vyleesi)Authorised in the United States, no EU authorisationOutside the French channel
RetatrutideCandidate in clinical development, no authorisationOutside the pharmaceutical channel
BPC-157, TB-500, Semax, EpitalonNo authorisationResearch material only

The case of oxytocin illustrates the logic: the same peptide hormone exists as an injectable hospital medicine and as a laboratory reference material. It is not the molecule that decides the status, it is the product, its presentation and its authorisation.

Retatrutide, for its part, is studied in advanced-phase clinical trials; our clinical literature and GLP-1 receptor pages summarise what those trials measured. For as long as it holds no marketing authorisation, it is available in pharmacies in no form whatever.

What a seller of research materials may say — and may not

A supplier of reference materials may describe the identity of a compound, its purity, its mass, its storage conditions and the published scientific literature about it. It may not promise an effect in humans, propose a dosage, or present its product as a treatment.

These two registers do not mix. That is why the pages in our catalogue describe specifications and point to literature dossiers, but contain no indication of use.

What this means for the buyer

Buying a reference material means buying a product intended for in-vitro laboratory research. Administering it to humans or animals falls outside that framework: the substance has been the subject of no safety evaluation and no authorisation for that use.

The buyer remains responsible for the use they make of a product and for its compliance with the applicable law. In case of doubt about a particular situation, only a lawyer can answer. Our legal notice sets out the conditions applicable to our sales.

Sport: the World Anti-Doping Agency list

For athletes subject to testing, a further rule applies. The World Anti-Doping Agency (WADA) prohibited list, applied in France by the French anti-doping agency, covers several peptides sold as research materials:

  • BPC-157, cited among the non-approved substances (section S0);
  • the GHRH analogues and the growth hormone secretagogues — including CJC-1295, Ipamorelin and GHRP-6 (section S2);
  • thymosin β4 and its derivatives, including TB-500 (section S2).

The list is updated every year; only the version in force is authoritative.

Frequently asked questions

Can BPC-157 be bought in a pharmacy?

No. BPC-157 holds no marketing authorisation in France; it therefore cannot be dispensed in a pharmacy, with or without a prescription.

Is retatrutide available on prescription?

No. Retatrutide has no marketing authorisation; no doctor can prescribe it as an authorised medicine and no pharmacy can dispense it.

Are research peptides legal in France?

The sale of reference materials intended for research, without therapeutic presentation, does not fall under marketing authorisation. Any presentation or use as a medicine does, on the other hand, fall under medicines regulation. This article is general information, not legal advice.

Why do some sites talk about “peptides without a prescription”?

Because the phrase attracts searches. It is nonetheless inaccurate: a reference material is not a medicine, and the notion of a prescription does not apply to it.

Related dossiers

All research dossiers → · Catalogue → · Glossary →